Du är här

2014-05-27

Ablynx: ABLYNX TO PRESENT AT THE ANNUAL JEFFERIES 2014 GLOBAL HEALTHCARE CONFERENCE

GHENT, Belgium, 27 May 2014
-Ablynx[Euronext Brussels: ABLX]

today announces it will present at the annual Jefferies 2014 Global Healthcare
Conference at the Grand Hyatt in New York City on Monday, 2ndJune 2014 at
11:30 a.m. EST (05:30 p.m. CET).

The presentation, followed by a Q&A, will be hosted by Dr Edwin Moses, CEO of
Ablynx. The presentation will provide an update on the Company's proprietary
key clinical assets, its partnered programmes and the outlook for the near
term future.

The presentation will be webcast live and can be accessed on the day via
thislinkor the Ablynx website atwww.ablynx.com. A replay of the webcast will
be available on the Company's website for 30 days following the presentation.
To ensure a timely connection, it is recommended that users register at least
10 minutes prior to the scheduled webcast.

About Ablynx

Ablynxis a biopharmaceutical company engaged in the discovery and development
ofNanobodies®, a novel class of therapeutic proteins based on single-domain
antibody fragments, for a range of serious human diseases, including
inflammation, haematology, oncology and pulmonary disease. Today, the Company
has more than30 programmes in the pipelineand seven Nanobodies at clinical
development stage. Ablynx has ongoing research collaborations and significant
partnerships with major pharmaceutical companies including AbbVie, Boehringer
Ingelheim, Merck&Co, Merck Serono and Novartis. The Company is headquartered
in Ghent, Belgium. More information can be found onwww.ablynx.com.

For more information, please contact

Ablynx:

Dr Edwin Moses
CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
+32 (0)473 39 50 68
e: edwin.moses@ablynx.com

Marieke Vermeersch
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e: marieke.vermeersch@ablynx.com

Follow us on Twitter @AblynxABLX

Ablynx media relations
Consilium Strategic Communications:

Mary-Jane Elliott, Amber Bielecka, Lindsey Neville
t: +44 203 709 5700
e: ablynx@consilium-comms.com

pdf format of the press release
http://hugin.info/137912/R/1788913/614744.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Ablynx via Globenewswire

HUG#1788913

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.